LEO Pharma Receives Marketing Authorisation for Kyntheum® (Brodalumab), a New Biologic for the Treatment of Moderate-to-

Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.

For more information, visit http://www.leo-pharma.com

Subscribe to our YouTube channel: http://www.youtube.com/leopharmaglobal

Follow us on Twitter: http://www.twitter.com/leohealthyskin

Visit us at LinkedIn: http://www.linkedin.com/company/leo-pharma

Global media contacts Henrik Heskjaer Kyndlev Global Communications Manager Email: HDTDK@leo-pharma.com Mobile: +45-3140-6180

References   

1.    European Commission, Community register of medicinal products for human use, Kyntheum(R) (brodalumab). Available from:  http://ec.europa.eu/health/documents/community-register/html... (Accessed July 2017)

2.    Campa M, et al. Dermatol Ther. 2016;6:1-12

3.    Coimbra S, et al. Core Evidence. 2014;9:89-97

4.    World Health Organization (WHO). Global Report on Psoriasis. Available from: http://apps.who.int/iris/bitstream/10665...  (Accessed July 2017)

5.    The International Federation of Psoriasis Associations. Available at: https://ifpa-pso.com (Accessed July 2017)

6.    Ortonne J, et al. Eur J Dermatol. 2004;14:41-45

7.    Beringer A, et al. Trends Mol Med. 2016; 22: 230-41

8.    Russell CB, et al. J Immunol. 2014; 192: 3828-36

9.    Lebwohl M, et al. N Engl J Med 2015;373:1318-28

10.   Papp K, et al. Br J Dermatol. 2016;175:273-286

11.   European Medicines Agency. EPAR summary for the public: Cosentyx. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-S...  (Accessed July 2017)

12.   Taltz(R). Summary of Product Characteristics 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-P...   (Accessed July 2017)  

13.   Stelara(R). Summary of Product Characteristics 2009. Available from: https://www.medicines.org.uk/emc/medicin... (Accessed July 2017)

14.   Enbrel(R). Summary of Product Characteristics 2000. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... (Accessed July 2017)

15.   Humira(R). Summary of Product Charateristics 2003. Available from: https://www.medicines.org.uk/emc/medicin... (Accessed July 2017)

16.   Remicade(R). Summary of Product Characteristics 1999. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-P...  (Accessed July 2017)

17.   National Institute for Health and Care Excellence (NICE) Psoriasis: assessment and management guidelines. Available at: https://www.nice.org.uk/guidance/cg153/chapter/1-Guidance#sy... (Accessed July 2017)

18.   Attia A, et al. Clin Drug Investig. 2017; DOI: 10.1007/s40261-017-0500-9

19.   Lebwohl, M. et al. The American Academy of Dermatology annual meeting 2017. Poster 4908

20.   Papp K, et al. N Engl J Med. 2012;336:1181-9

21.   Supplement to: Lebwohl M, et al. N Engl J Med. 2015;373:1318-28

22.   Gordon KB, et al. Br J Dermatol. 2014;170:705-15

23.   Reich K.  Eur Acad Dermatol Venereol. 2012; 26(2):3-11

24.   Gelfand JM, et al. JAMA. 2016;296:1735-41

25.   Ahlehoff O, et al. Eur Heart J. 2012;33:2054-64

26.   Lowes MA, et al. Immunology of psoriasis. Ann Rev Immunol. 2014;32:227-35

27.   Langan SM, et al. J Invest Dermatol. 2012 Mar; 132(3 0 1): 556-562

28.   Dalgard F, et al. JID. 2015;135(4), 984-991

Photo: http://photos.prnewswire.com/prnh/201302...